Welcome to the e-CCO Library!

P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F.S. Macaluso1, W. Fries2, A. Viola2, A. Centritto2, M. Cappello3, E. Giuffrida3, A.C. Privitera4, G. Piccillo4, A. Magnano5, E. Vinci5, R. Vassallo6, A. Trovatello7, N. Belluardo8, E. Giangreco8, S. Camilleri9, S. Garufi9, C. Bertolami10, M. Ventimiglia1, S. Renna1, R. Orlando1, G. Rizzuto1, M. Grova1, A. Orlando1

Created: Thursday, 30 January 2020, 10:12 AM
P425: Biosimilar infliximab in real-life Crohn's disease treatment in anti-TNF-alpha naïve and non-naïve patients in comparison to biologic originator: a comparative observational cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kaniewska M.*1, Moniuszko A.1, Maciejewska K.1, Rydzewska G.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P425: Comparison of therapeutic choices in biologic experienced Crohn’s disease and ulcerative colitis patients in Europe: discontinuation rates because of disease improvements
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Franceschetti*1, A. Baskett2, H. McKenzie2

Created: Friday, 22 February 2019, 9:49 AM
P425: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of ustekinumab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Farrag*1,2, M. Rohlfs3, J. Ruppert3, F-P. Armbruster3, J. Stein1,2

Created: Friday, 22 February 2019, 9:41 AM
P425: Proactive measurement of infliximab trough levels vs. clinical management in inflammatory bowel disease: multicentre study
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Elosua González1*, D. Oyón Lara1, P. Sanz Segura2, M. Arroyo Villariño3, S. García López2, C. Rodríguez Gutiérrez1, Ó. Nantes Castillejo1

Created: Thursday, 21 February 2019, 9:14 AM
P425: Rates of tuberculosis infection in Crohn’s Disease patients before and during anti-tumor necrosis factor therapy
Year: 2022
Source: ECCO'22
Authors: GeorgievaPhD, A.C.(1);Atanassova, A.(1);Mirchev, M.(1);
Created: Friday, 11 February 2022, 3:52 PM
P425: Real-world evidence on effectiveness and safety of vedolizumab therapy for inflammatory bowel disease in Taiwan: Results from the TSIBD registry (VIOLET Study)
Year: 2021
Source: ECCO'21 Virtual
Authors: Wei , S.C.(1);Lin , W.C.(2);Chang , C.H.(3);Tu , C.H.(1);Feng , I.C.(4);Shieh , M.J.(5);Chung , C.S.(6);Yen , H.H.(7);Chou , J.W.(8);Tai , W.C.(9);Wong , J.M.(1);Liu , Y.H.(10);Huang , T.Y.(11);Chuang , C.H.(12);Tsai , T.J.(13);Chiang , F.F.(14);Lu , C.Y.(15);Hsu , W.H.(15);Yu , F.J.(15);Chao , T.H.(14);Wu , D.C.(15);Ho , A.S.(16);Lin , H.H.(17);Feng , C.L.(18);Wu , K.L.(9);Wong , M.W.(19);Tung , C.C.(20);Lin , C.C.(17);Chen , C.C.(3);Hu , H.M.(21);Lu , L.S.(22);Wang , H.S.(23);Wu , I.C.(15);Kuo , H.Y.(24,25);Wu , J.F.(26);Shih , H.Y.(15);Ni , Y.H.(27);Tang , S.L.(28);Chang , H.C.(28);Chen , P.H.(28);
Created: Wednesday, 2 June 2021, 4:12 PM
P425: The utility of intestinal ultrasound to inform clinical decision making
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yeaman, F.(1)*;Panaccione, R.(1);Ma, C.(1);Lu, C.(1);Seow, C.(1);Kaplan, G.(1);Maracle, B.(1);Novak, K.(1);
Created: Friday, 14 July 2023, 11:05 AM
P426 In failure of non-optimised adalimumab (ADA) with therapeutic serum levels, a change in biotherapy class is greater than an intensification of ADA dose in IBD patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

X. Roblin1, C. genin1, N. williet1, P. veyrard1, G. boschetti2, A.E. berger3, B. flourie2, S. nancey2, S. Paul3

Created: Thursday, 30 January 2020, 10:12 AM
P426: Association Between vedolizumab therapy outcome and Pre-treatment DUBLIN Score & CRP-Albumin Ratio in Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: McCormick, E.(1);Singh, P.(1);Kevans, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P426: Health-Related Quality of Life and Work Productivity in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study
Year: 2021
Source: ECCO'21 Virtual
Authors: Correa, G.J.(1);Yantorno, M.(1);Olivera Sendra, P.(2,3);Lasa, J.S.(2,4);Lubrano, P.(3);Balderramo, D.C.(5,6);Zubiaurre, I.(4);Ruffinengo, O.(7);Brion, L.(8);Leonardi, D.B.(8);El-Hakeh, J.(8);Guimaraens, P.N.(8);Sambuelli, A.(9);
Created: Wednesday, 2 June 2021, 4:12 PM
P426: Lympocytosis in patients with inflammatory bowel disease treated with anti-TNFa agents: is it significant?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Soufleris*1, N. Kafalis1, M. Charalampidis1, K. Fasoulas1, I. Pilpilidis1, G. Lazaraki1, D. Tzilves1, D. Markala2

Created: Friday, 22 February 2019, 9:41 AM
P426: Meta-analysis of endorectal advancement flap vs. ligation of the intersphincteric fistula tract for Crohn’s and cryptoglandular high perianal fistulas
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.E. Stellingwerf*, E.M. van Praag, W.A. Bemelman, C.J. Buskens

Created: Thursday, 21 February 2019, 9:14 AM
P426: Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Zittan*1, 2, O. B. Kelly1, B. Kabakchiev1, G. C. Nguyen1, K. Croitoru1, A. H. Steinhart1, M. S. Silverberg1

Created: Friday, 22 February 2019, 9:49 AM
P426: Sex and sexuality in IBD - the pediatric gastroenterologists' point of view
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Anafy, A.(1,2);Cohen, S.(1,2);Matar, M.(3);Shouval, D.S.(2,3);Shamir, R.(2,3);Weintraub, Y.(2,3)*;
Created: Friday, 14 July 2023, 11:05 AM
P426: Supra-therapeutic infliximab levels are not associated with a higher risk of infection in IBD patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Greener T.*1, Kabakchiev B.2, Silverberg M.3

Created: Wednesday, 20 February 2019, 10:36 AM
P427 A hybrid approach of handling missing data in inflammatory bowel disease (IBD) trials: results from VISIBLE 1 and VARSITY
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Chen1, S. Hunter2, K. Kisfalvi3, R.A. Lirio4

Created: Thursday, 30 January 2020, 10:12 AM
P427: Development of an index that predicts escalation of therapy at an outpatient appointment in patients with known ulcerative colitis (UC)
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Walsh1*, P. Seeva1, C. Hinds2, V. Sexton3, O. Brain1, S. Keshav1, H. Uhlig1, J. Geddes3, G. Goodwin3, M. Peters4, G. Collins5, S. Travis1

Created: Thursday, 21 February 2019, 9:14 AM
P427: Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Kim, J.S.(1);Leung, W.K.(2);Wu, D.C.(3);Lindner, D.(4);Fadeeva, O.(5);Demuth, D.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P427: Exploring phenotype and treatment of inflammatory bowel disease in the elderly
Year: 2022
Source: ECCO'22
Authors: Gaglani, R.(1);Balarajah, S.(1);Williams, H.(1);Hicks, L.(1);
Created: Friday, 11 February 2022, 3:52 PM